Skip to content
Bending the Curve Trial by Trial
?

NWTS-5

National Wilms Tumor Study-5: Therapeutic Trial and Biology Study

Phase 3N = 2,021NCT00002611

Population
Previously untreated children with Wilms tumour, clear cell sarcoma of the kidney or rhabdoid tumour of the kidney
Design
North American cooperative-group study of stage- and histology-specific therapy with a biology study. Grundy 2005 assayed tumours from 2,021 previously untreated children treated between August 1995 and June 2002 (favourable or anaplastic histology Wilms tumour, clear cell sarcoma of the kidney, rhabdoid tumour of the kidney); Dome 2006 reports 2,596 patients enrolled. The registry record NCT00002611 gives actual enrolment 3,031 (start July 1995).
Arms
  • Stage- and histology-specific therapy (experimental): Therapy assigned by stage and histology (details in the individual NWTS-5 reports)
People
Grundy PE, National Wilms Tumor Study Group
Primary publication: Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312-21. PubMedDOI

Appears in

Sources

  1. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312-21.

    PubMedDOI